John S. Tzartos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
John S. Tzartos has a total of 422 co-authors. Here are the top co-authors by number of shared publications:
- Georgios Tsivgoulis
Second Department of Neurology, National and Kapodistrian University of Athens, Attikon University Hospital, Greece (G.T.).
23 shared publications - Sotirios Giannopoulos
Second Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece
20 shared publications - Dimitrios K. Kitsos
Second Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece
11 shared publications - Dimitrios Tzanetakos
Second Department of Neurology, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece
11 shared publications - Georgios P. Paraskevas
Neurochemistry and Biological Markers Unit, 1st Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Eginition Hospital, Vass. Sophias Ave. 74, 11528 Athens, Greece
10 shared publications - Vasileios Giannopapas
Second Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece
10 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
A new bioluminescent cell-based assay for the detection of alpha-3 acetylcholine receptor antibodies: a multicentre comparison with current methods
Autoimmune autonomic ganglionopathy (AAG) is a disorder of the autonomic nervous system associated with autoantibodies against the α3 subunit of the ganglionic acetylcholine receptor (gnACHR). gnACHR antibodies exert their effects via receptor internalisation, but most current gnACHR diagnostic assays only detect antibody binding. Hence, we developed a new bioluminescent cell-based assay (BLIA) to measure internalising gnACHR antibodies. The BLIA was performed by incubating patient sera with live IMR-32 cells that express surface gnACHR. Remaining surface gnACHR was quantified using a novel split luciferase system with NanoBiT conjugated detecting antibodies. The percentage of receptor internalisation was calculated with comparison to cells incubated with reference sera, with > 20% receptor internalisation considered positive for gnACHR antibodies. The BLIA was validated using 46 samples from 20 AAG patients and 203 control samples. Subsequent comparisons to four existing assays were performed: (1) radioimmunoprecipitation assay (RIPA), (2) flow cytometric internalisation assay (FCIA), (3) cell-based assay (CBA-1) where HEK293T cells were transfected with α3β4 gnACHR subunits and (4) optimised CBA-2 with additional transfection of RIC3 and NACHO and incubation with 1 mM nicotine. The BLIA detected gnACHR antibodies with 100% sensitivity and 100% specificity (AUROC = 1.0) with detection of the internalising effects of antibodies to concentrations of < 0.1 pM. There was complete qualitative agreement with CBA-2 (Cohen’s kappa = 1). No statistical difference between these two assays and the RIPA, which had slightly lower sensitivity (98%) and specificity (95%), or the FCIA, which had slightly reduced specificity (95%), was found. CBA-1 had significantly lower sensitivity (69%, p = 0.0003). Overall, the BLIA had perfect clinical sensitivity and specificity in detecting gnACHR antibodies in AAG patients and detection of the functional effects of gnACHR antibodies via internalisation offers a suitable alternative to current assays. Further assessment of its possible role in monitoring disease severity or treatment response is warranted.
- 8 August 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Open AccessA new bioluminescent cell-based assay for the detection of alpha-3 acetylcholine receptor antibodies: a multicentre comparison with current methods
Autoimmune autonomic ganglionopathy (AAG) is a disorder of the autonomic nervous system associated with autoantibodies against the α3 subunit of the ganglionic acetylcholine receptor (gnACHR). gnACHR antibodies exert their effects via receptor internalisation, but most current gnACHR diagnostic assays only detect antibody binding. Hence, we developed a new bioluminescent cell-based assay (BLIA) to measure internalising gnACHR antibodies. The BLIA was performed by incubating patient sera with live IMR-32 cells that express surface gnACHR. Remaining surface gnACHR was quantified using a novel split luciferase system with NanoBiT conjugated detecting antibodies. The percentage of receptor internalisation was calculated with comparison to cells incubated with reference sera, with > 20% receptor internalisation considered positive for gnACHR antibodies. The BLIA was validated using 46 samples from 20 AAG patients and 203 control samples. Subsequent comparisons to four existing assays were performed: (1) radioimmunoprecipitation assay (RIPA), (2) flow cytometric internalisation assay (FCIA), (3) cell-based assay (CBA-1) where HEK293T cells were transfected with α3β4 gnACHR subunits and (4) optimised CBA-2 with additional transfection of RIC3 and NACHO and incubation with 1 mM nicotine. The BLIA detected gnACHR antibodies with 100% sensitivity and 100% specificity (AUROC = 1.0) with detection of the internalising effects of antibodies to concentrations of < 0.1 pM. There was complete qualitative agreement with CBA-2 (Cohen’s kappa = 1). No statistical difference between these two assays and the RIPA, which had slightly lower sensitivity (98%) and specificity (95%), or the FCIA, which had slightly reduced specificity (95%), was found. CBA-1 had significantly lower sensitivity (69%, p = 0.0003). Overall, the BLIA had perfect clinical sensitivity and specificity in detecting gnACHR antibodies in AAG patients and detection of the functional effects of gnACHR antibodies via internalisation offers a suitable alternative to current assays. Further assessment of its possible role in monitoring disease severity or treatment response is warranted.
- Open Access
- 9 March 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (3) , 194
The predictive value of serum neurofilament light chain in achieving no evidence of disease activity-3 (NEDA-3) status in treatment-naïve patients with multiple sclerosis
Background: Serum neurofilament light chain (sNfL) has emerged as a biomarker reflecting neuroaxonal damage. The role of sNfL in predicting clinical outcome and guiding therapeutic management in multiple sclerosis (MS) is an ongoing research topic. We sought to evaluate sNfL utility for the prediction of achieving No Evidence of Disease Activity-3 (NEDA-3) among MS patients. Methods: We conducted a prospective cohort study including MS patients with a single sNfL measurement at first clinical evaluation. Follow-up was performed every 6 months/clinical relapse and included clinical and MRI evaluation. The main outcome was NEDA-3 achievement during follow-up. sNfL levels were measured, using single-molecule-array (SIMOA) assay. sNfL age- and BMI-normalized Z-scores > 1.5 were defined as high. Linear regression analyses were performed to identify predictors of baseline sNfL Z-score and multivariable Cox proportional hazard regression models were used to evaluate predefined outcomes. Results: We included 125 patients [age at sNfL measurement:40 ± 12, 30% men, 82% relapsing–remitting and 18% progressive MS]:37 treatment-naïve patients, 88 patients under Disease-Modifying-Treatment (DMT) with 19.1 (Interquartile Range:12.1–24.5) months median follow-up. Prior DMT use [β:-0.93; 95%CI:-1.48– -0.38 p -value:0.001] was negatively associated with baseline sNfL Z-scores. Gadolinium-enhancing lesions were associated with higher sNfL Z-scores [adjusted standardized linear regression coefficient-β:0.68; 95%CI:0.03–1.32; p -value:0.036], contrary to T2-weighted lesion activity (β:0.40; 95%CI:0.17–0.94; p -value:0.232). In treatment-naive patients, high sNfL Z-scores were associated with lower probability of achieving NEDA-3 during follow-up [hazard-ratio:0.35; 95%CI:0.13–0.96; p -value:0.041]. Conclusions: This study demonstrated that gadolinium-enhancing lesions, indicative of active inflammation, are associated with elevated sNfL Z-scores, contrary to T2-weighted lesion-activity and highlights the prognostic value of sNfL in achieving NEDA-3 in treatment-naive patients.
- 9 March 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (3) , 194
Open AccessThe predictive value of serum neurofilament light chain in achieving no evidence of disease activity-3 (NEDA-3) status in treatment-naïve patients with multiple sclerosis
Background: Serum neurofilament light chain (sNfL) has emerged as a biomarker reflecting neuroaxonal damage. The role of sNfL in predicting clinical outcome and guiding therapeutic management in multiple sclerosis (MS) is an ongoing research topic. We sought to evaluate sNfL utility for the prediction of achieving No Evidence of Disease Activity-3 (NEDA-3) among MS patients. Methods: We conducted a prospective cohort study including MS patients with a single sNfL measurement at first clinical evaluation. Follow-up was performed every 6 months/clinical relapse and included clinical and MRI evaluation. The main outcome was NEDA-3 achievement during follow-up. sNfL levels were measured, using single-molecule-array (SIMOA) assay. sNfL age- and BMI-normalized Z-scores > 1.5 were defined as high. Linear regression analyses were performed to identify predictors of baseline sNfL Z-score and multivariable Cox proportional hazard regression models were used to evaluate predefined outcomes. Results: We included 125 patients [age at sNfL measurement:40 ± 12, 30% men, 82% relapsing–remitting and 18% progressive MS]:37 treatment-naïve patients, 88 patients under Disease-Modifying-Treatment (DMT) with 19.1 (Interquartile Range:12.1–24.5) months median follow-up. Prior DMT use [β:-0.93; 95%CI:-1.48– -0.38 p -value:0.001] was negatively associated with baseline sNfL Z-scores. Gadolinium-enhancing lesions were associated with higher sNfL Z-scores [adjusted standardized linear regression coefficient-β:0.68; 95%CI:0.03–1.32; p -value:0.036], contrary to T2-weighted lesion activity (β:0.40; 95%CI:0.17–0.94; p -value:0.232). In treatment-naive patients, high sNfL Z-scores were associated with lower probability of achieving NEDA-3 during follow-up [hazard-ratio:0.35; 95%CI:0.13–0.96; p -value:0.041]. Conclusions: This study demonstrated that gadolinium-enhancing lesions, indicative of active inflammation, are associated with elevated sNfL Z-scores, contrary to T2-weighted lesion-activity and highlights the prognostic value of sNfL in achieving NEDA-3 in treatment-naive patients.
- Open Access
Clinical, Cognitive and Demographic Determinants of Work Participation in Multiple Sclerosis: A Multicenter Cross-Sectional Study
Background and Objectives: Employment is a major determinant of quality of life in people with multiple sclerosis (pwMS). This multicenter cross-sectional study aimed to identify which commonly studied demographic, disease-related, clinical, cognitive, and psychological variables, alongside the presence of lower urinary tract symptoms (LUTS), predict employment status in pwMS. Materials and Methods: Seventy-eight pwMS were classified as either full-time employed (n = 41) or non-employed (n = 37). Participants underwent clinical and neuropsychological assessment including disability status (Expanded Disability Status Scale; EDSS), fatigue (Modified Fatigue Impact Scale; MFIS), information processing speed (Symbol Digit Modalities Test; SDMT), depressive symptoms (Hospital Anxiety and Depression Scale-Depression; HADS-D), and LUTS status (presence/absence), alongside demographic and disease-related variables (sex, age, education level, relationship status, and disease duration). Results: Hierarchical binary logistic regression indicated that higher information processing speed was associated with higher odds of employment (OR = 1.11, p = 0.008), whereas the presence of LUTS was associated with lower odds of employment (OR = 0.13, p = 0.026). Disability severity, fatigue, depressive symptoms, demographic characteristics, and disease duration did not contribute in the final model (p > 0.05). Conclusions: Information processing speed and urinary dysfunction were associated with employment status in pwMS. Within the present sample, the multivariable model including these variables showed good discrimination between employed and non-employed participants. The findings should be interpreted as exploratory, and they require further confirmation in independent cohorts before any potential application is considered.
Open AccessClinical, Cognitive and Demographic Determinants of Work Participation in Multiple Sclerosis: A Multicenter Cross-Sectional Study
Background and Objectives: Employment is a major determinant of quality of life in people with multiple sclerosis (pwMS). This multicenter cross-sectional study aimed to identify which commonly studied demographic, disease-related, clinical, cognitive, and psychological variables, alongside the presence of lower urinary tract symptoms (LUTS), predict employment status in pwMS. Materials and Methods: Seventy-eight pwMS were classified as either full-time employed (n = 41) or non-employed (n = 37). Participants underwent clinical and neuropsychological assessment including disability status (Expanded Disability Status Scale; EDSS), fatigue (Modified Fatigue Impact Scale; MFIS), information processing speed (Symbol Digit Modalities Test; SDMT), depressive symptoms (Hospital Anxiety and Depression Scale-Depression; HADS-D), and LUTS status (presence/absence), alongside demographic and disease-related variables (sex, age, education level, relationship status, and disease duration). Results: Hierarchical binary logistic regression indicated that higher information processing speed was associated with higher odds of employment (OR = 1.11, p = 0.008), whereas the presence of LUTS was associated with lower odds of employment (OR = 0.13, p = 0.026). Disability severity, fatigue, depressive symptoms, demographic characteristics, and disease duration did not contribute in the final model (p > 0.05). Conclusions: Information processing speed and urinary dysfunction were associated with employment status in pwMS. Within the present sample, the multivariable model including these variables showed good discrimination between employed and non-employed participants. The findings should be interpreted as exploratory, and they require further confirmation in independent cohorts before any potential application is considered.
- Open Access
- 10 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1378
Neuropathic Pain in Neuromyelitis Optica Spectrum Disorders: Prevalence and Management Strategies—A Systematic Review and Meta-Analysis
Introduction: Neuropathic pain (NP) in neuromyelitis optica spectrum disorder (NMOSD) represents a significant and often under-recognized complication arising from central nervous system (CNS) lesions. Unlike other demyelinating disorders, NMOSD involves a distinct immunopathogenesis primarily driven by aquaporin-4 antibodies (AQP4-IgG), leading to severe inflammatory damage. NP is typically the consequence of inflammatory damage to the spinothalamic tract or dorsal columns, resulting in both acute and chronic pain syndromes. Methods: A systematic review and meta-analysis were conducted following a comprehensive search of Medline and Scopus, identifying nine eligible studies reporting on NP in NMOSD. Results: Pooled prevalence was estimated using a random-effects metaprop meta-analysis with Freeman–Tukey transformation and REML-based heterogeneity estimation. The pooled prevalence of NP among patients with NMOSD was 56.2% (95% CI: 41.7–70.1%; I2 = 95.3%, p < 0.001). Sensitivity analysis including only AQP4-IgG+ cohorts revealed a prevalence of 63.2% (95% CI: 23.4–94.7%; I2 = 98.1%, p < 0.001). No significant difference was found between mixed and AQP4-IgG+-only populations (53.05% vs. 63.27%, p = 0.63). Meta-regression showed no significant associations between NP prevalence and age (β = 0.01, p = 0.33) or disability (β = 0.08, p = 0.18). Qualitative synthesis demonstrated an association between thoracic spinal cord lesions and NP, and also indicated that NP was often resistant and refractory to standard pharmacologic therapies. Conclusions: NP affects one in two NMOSD patients, and is associated with thoracic spinal cord lesions. In comparison with multiple sclerosis, NP in NMOSD is primarily structural and immunopathological in origin. Treatment strategies remain inadequate, emphasizing the need for early recognition and a disease-specific therapeutic approach.
- 10 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1378
Open AccessNeuropathic Pain in Neuromyelitis Optica Spectrum Disorders: Prevalence and Management Strategies—A Systematic Review and Meta-Analysis
Introduction: Neuropathic pain (NP) in neuromyelitis optica spectrum disorder (NMOSD) represents a significant and often under-recognized complication arising from central nervous system (CNS) lesions. Unlike other demyelinating disorders, NMOSD involves a distinct immunopathogenesis primarily driven by aquaporin-4 antibodies (AQP4-IgG), leading to severe inflammatory damage. NP is typically the consequence of inflammatory damage to the spinothalamic tract or dorsal columns, resulting in both acute and chronic pain syndromes. Methods: A systematic review and meta-analysis were conducted following a comprehensive search of Medline and Scopus, identifying nine eligible studies reporting on NP in NMOSD. Results: Pooled prevalence was estimated using a random-effects metaprop meta-analysis with Freeman–Tukey transformation and REML-based heterogeneity estimation. The pooled prevalence of NP among patients with NMOSD was 56.2% (95% CI: 41.7–70.1%; I2 = 95.3%, p < 0.001). Sensitivity analysis including only AQP4-IgG+ cohorts revealed a prevalence of 63.2% (95% CI: 23.4–94.7%; I2 = 98.1%, p < 0.001). No significant difference was found between mixed and AQP4-IgG+-only populations (53.05% vs. 63.27%, p = 0.63). Meta-regression showed no significant associations between NP prevalence and age (β = 0.01, p = 0.33) or disability (β = 0.08, p = 0.18). Qualitative synthesis demonstrated an association between thoracic spinal cord lesions and NP, and also indicated that NP was often resistant and refractory to standard pharmacologic therapies. Conclusions: NP affects one in two NMOSD patients, and is associated with thoracic spinal cord lesions. In comparison with multiple sclerosis, NP in NMOSD is primarily structural and immunopathological in origin. Treatment strategies remain inadequate, emphasizing the need for early recognition and a disease-specific therapeutic approach.
- Open Access
- 7 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1329
Optical Coherence Tomography Angiography-Derived Peripapillary Vessel Density Findings in Multiple Sclerosis
Background/Objectives: Multiple sclerosis (MS)-related optic neuritis (ON) results in thinning of the peripapillary nerve fiber layer (pRNFL) which tends to be temporal quadrant-predominant. Optical coherence tomography angiography (OCTA) enables visualization of the retinal vasculature. Prior studies have shown reduced peripapillary vessel density (VD) in MS but data on the quadrantic pattern of peripapillary VD loss are limited. Our objective was to investigate the pattern of OCTA-derived peripapillary VD reduction in MS. Methods: People with MS (PwMS) and healthy controls (HC) underwent optic disc OCTA scans (Solix, Optovue) and VD was derived for the peripapillary region and quadrants. Eyes with ON within six months were excluded. Analyses were performed with generalized estimating equations models and standardized coefficients are presented. Results: We included 50 eyes from 29 PwMS (12 ON, 38 non-ON) and 12 eyes from 6 HC. VD in the peripapillary region was lower in MS ON eyes compared to HC with the largest effect size observed in the temporal quadrant (average: −1.47, p < 0.001; superior: −1.08, p = 0.006; inferior: −0.94; p = 0.017; temporal: −1.55; p < 0.001; nasal: −1.06, p = 0.007). In MS non-ON eyes, only temporal VD was significantly lower compared to HC eyes (temporal: −0.77, p = 0.004). Moderate to strong correlations were observed between OCT and corresponding OCTA metrics from the same regions. Conclusions: Our findings suggest that vascular alterations in the peripapillary region may exhibit a temporal quadrant predominant pattern. Larger studies are needed to further characterize the patterns and temporal evolution of retinal peripapillary vascular injury in MS.
- 7 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1329
Open AccessOptical Coherence Tomography Angiography-Derived Peripapillary Vessel Density Findings in Multiple Sclerosis
Background/Objectives: Multiple sclerosis (MS)-related optic neuritis (ON) results in thinning of the peripapillary nerve fiber layer (pRNFL) which tends to be temporal quadrant-predominant. Optical coherence tomography angiography (OCTA) enables visualization of the retinal vasculature. Prior studies have shown reduced peripapillary vessel density (VD) in MS but data on the quadrantic pattern of peripapillary VD loss are limited. Our objective was to investigate the pattern of OCTA-derived peripapillary VD reduction in MS. Methods: People with MS (PwMS) and healthy controls (HC) underwent optic disc OCTA scans (Solix, Optovue) and VD was derived for the peripapillary region and quadrants. Eyes with ON within six months were excluded. Analyses were performed with generalized estimating equations models and standardized coefficients are presented. Results: We included 50 eyes from 29 PwMS (12 ON, 38 non-ON) and 12 eyes from 6 HC. VD in the peripapillary region was lower in MS ON eyes compared to HC with the largest effect size observed in the temporal quadrant (average: −1.47, p < 0.001; superior: −1.08, p = 0.006; inferior: −0.94; p = 0.017; temporal: −1.55; p < 0.001; nasal: −1.06, p = 0.007). In MS non-ON eyes, only temporal VD was significantly lower compared to HC eyes (temporal: −0.77, p = 0.004). Moderate to strong correlations were observed between OCT and corresponding OCTA metrics from the same regions. Conclusions: Our findings suggest that vascular alterations in the peripapillary region may exhibit a temporal quadrant predominant pattern. Larger studies are needed to further characterize the patterns and temporal evolution of retinal peripapillary vascular injury in MS.
- Open Access
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (8) , e214150
Subunit-Specific Immunodominance in Clinically Distinct Populations With AChR+ Myasthenia Gravis
Myasthenia gravis (MG) is a chronic antibody-mediated autoimmune neuromuscular disorder causing fluctuating muscle weakness due to autoantibodies that target the acetylcholine receptor (AChR) in the neuromuscular junction (NMJ). Despite extensive research, MG remains unpredictable and heterogeneous, underscoring the need for better insight into disease pathogenesis and clinical course. The objective of this study was to identify clinical and immunologic disease-related parameters that correlate with disease severity. This large-scale, multicenter, cross-sectional study included prospectively recruited patients with MG and MG serum samples procured from reputable biobanks. Inclusion criteria required an MG clinical presentation and a positive anti-AChR immunoglobulin G (IgG) titer (≥0.5 nM), confirmed by 2 independent tests. Enrolled patients underwent profiling of subunit-specific anti-AChR IgG titers. Disease severity patterns and their relation to age, sex, disease onset, thymic involvement, anti-AChR titer, and anti-AChR subunit immunodominance were investigated. The study included 513 patients with MG (50.5% female) with a median age of 64 years (range 14-98.5). Extended clinical data were available for 232 patients. Anti-AChR titers increased monotonically with disease severity (ρ = 0.31, 95% CI 0.17-0.44, p < 0.0001) and were higher in female patients (median 14.6 nM vs 7.7 nM, 95% CI for Δ 2.1-7.3 nM, p < 0.0001) in whom higher antibody titers decreased monotonically with age. Male patients' titers were predominantly alpha-immunodominant (male 23.2% vs female 16.6%, 95% CI for Δ 0%-7.6%, p = 0.031), while female patients' titers were gamma-immunodominant (female 30% vs male 24.5%, 95% CI for Δ 2%-11%, p = 0.0027). Gamma immunodominance correlated with higher anti-AChR titer (ρ = 0.25, 95% CI 0.16-0.33, p < 0.0001) and severe (Myasthenia Gravis Foundation of America IV-V) disease (44% vs 27%, 95% CI for Δ 4%-34%, p = 0.0141). Unsupervised principal component analysis disclosed 2 distinct disease endotypes: female patients with moderate to severe early-onset MG, gamma subunit immunodominance, high anti-AChR titers, and frequent thymic hyperplasia (endotype A) and the remaining patients, mostly patients with late-onset MG, alpha subunit immunodominance, and low anti-AChR titers (endotype B). Two distinct MG endotypes emerge based on sex, age, thymic involvement, autoantibody titer, and immunoglobulin AChR subunit immunodominance-suggesting different underlying etiologies with potential implications for sex-dependent precision medicine, women's health, and the development of new therapeutic modalities for MG.
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (8) , e214150
Open AccessSubunit-Specific Immunodominance in Clinically Distinct Populations With AChR+ Myasthenia Gravis
Myasthenia gravis (MG) is a chronic antibody-mediated autoimmune neuromuscular disorder causing fluctuating muscle weakness due to autoantibodies that target the acetylcholine receptor (AChR) in the neuromuscular junction (NMJ). Despite extensive research, MG remains unpredictable and heterogeneous, underscoring the need for better insight into disease pathogenesis and clinical course. The objective of this study was to identify clinical and immunologic disease-related parameters that correlate with disease severity. This large-scale, multicenter, cross-sectional study included prospectively recruited patients with MG and MG serum samples procured from reputable biobanks. Inclusion criteria required an MG clinical presentation and a positive anti-AChR immunoglobulin G (IgG) titer (≥0.5 nM), confirmed by 2 independent tests. Enrolled patients underwent profiling of subunit-specific anti-AChR IgG titers. Disease severity patterns and their relation to age, sex, disease onset, thymic involvement, anti-AChR titer, and anti-AChR subunit immunodominance were investigated. The study included 513 patients with MG (50.5% female) with a median age of 64 years (range 14-98.5). Extended clinical data were available for 232 patients. Anti-AChR titers increased monotonically with disease severity (ρ = 0.31, 95% CI 0.17-0.44, p < 0.0001) and were higher in female patients (median 14.6 nM vs 7.7 nM, 95% CI for Δ 2.1-7.3 nM, p < 0.0001) in whom higher antibody titers decreased monotonically with age. Male patients' titers were predominantly alpha-immunodominant (male 23.2% vs female 16.6%, 95% CI for Δ 0%-7.6%, p = 0.031), while female patients' titers were gamma-immunodominant (female 30% vs male 24.5%, 95% CI for Δ 2%-11%, p = 0.0027). Gamma immunodominance correlated with higher anti-AChR titer (ρ = 0.25, 95% CI 0.16-0.33, p < 0.0001) and severe (Myasthenia Gravis Foundation of America IV-V) disease (44% vs 27%, 95% CI for Δ 4%-34%, p = 0.0141). Unsupervised principal component analysis disclosed 2 distinct disease endotypes: female patients with moderate to severe early-onset MG, gamma subunit immunodominance, high anti-AChR titers, and frequent thymic hyperplasia (endotype A) and the remaining patients, mostly patients with late-onset MG, alpha subunit immunodominance, and low anti-AChR titers (endotype B). Two distinct MG endotypes emerge based on sex, age, thymic involvement, autoantibody titer, and immunoglobulin AChR subunit immunodominance-suggesting different underlying etiologies with potential implications for sex-dependent precision medicine, women's health, and the development of new therapeutic modalities for MG.
- Open Access
- 29 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9531
The Biomarker Profile of Alzheimer’s Disease for Disease-Modifying Treatment Eligibility: Questions and Debates
Alzheimer’s disease (AD) is the most common cause of cognitive decline; currently, anti-amyloid monoclonal antibodies are available for clinical use as disease-modifying treatments, while many other substances are being tested in clinical trials. Molecular biomarkers for AD have been studied for more than two decades, and various guidelines and diagnostic recommendations have been published. However, there are still questions and controversies about the biomarker profile needed to confirm AD and the eligibility for such established treatments and clinical trials. Is amyloid positivity sufficient for eligibility, or is a biomarker for tau biochemistry/pathology also needed? What is the role of hybrid ratios combining amyloid and tau? Should we rely on plasma biomarkers alone? This review aimed to describe and discuss such questions and controversies.
- 29 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9531
Open AccessThe Biomarker Profile of Alzheimer’s Disease for Disease-Modifying Treatment Eligibility: Questions and Debates
Alzheimer’s disease (AD) is the most common cause of cognitive decline; currently, anti-amyloid monoclonal antibodies are available for clinical use as disease-modifying treatments, while many other substances are being tested in clinical trials. Molecular biomarkers for AD have been studied for more than two decades, and various guidelines and diagnostic recommendations have been published. However, there are still questions and controversies about the biomarker profile needed to confirm AD and the eligibility for such established treatments and clinical trials. Is amyloid positivity sufficient for eligibility, or is a biomarker for tau biochemistry/pathology also needed? What is the role of hybrid ratios combining amyloid and tau? Should we rely on plasma biomarkers alone? This review aimed to describe and discuss such questions and controversies.
- Open Access
- 1 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7410
APOE Genotyping in Cognitive Disorders: Preliminary Observations from the Greek Population
Alzheimer’s disease (AD) is the most common cause of cognitive decline. Among the various susceptibility genes, the gene of apolipoprotein E (APOE) is probably the most important. It may be present in three allelic forms, termed ε2, ε3 and ε4, and the most common genotype is the ε3/ε3. Recently, it has been observed that subjects with the ε4/ε4 genotype may show near-full penetrance of AD biology (pathology and biomarkers), leading to the suggestion that ε4 homozygosity may represent a distinct genetic type of AD. The aim of the present study was to investigate the role of ε4 homozygosity or heterozygosity in the presence or absence of the AD biomarker profile in patients with cognitive disorders in the Greek population. A total of 274 patients were included in the study. They underwent APOE genotyping and cerebrospinal fluid (CSF) biomarker profiling. The presence of ε4 was associated with a lower age of symptom onset and decreased amyloid biomarkers (irrespective to AD or non-AD profiles), and predicted the presence of an AD profile by a positive predictive value approaching 100%. In conclusion, the ε4 allele has a significant effect on the risk and clinical parameters of cognitive impairment and AD in the Greek population, while the ε4/ε4 genotype may be highly indicative of the (co)existence of AD in cognitively impaired patients.
- 1 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7410
Open AccessAPOE Genotyping in Cognitive Disorders: Preliminary Observations from the Greek Population
Alzheimer’s disease (AD) is the most common cause of cognitive decline. Among the various susceptibility genes, the gene of apolipoprotein E (APOE) is probably the most important. It may be present in three allelic forms, termed ε2, ε3 and ε4, and the most common genotype is the ε3/ε3. Recently, it has been observed that subjects with the ε4/ε4 genotype may show near-full penetrance of AD biology (pathology and biomarkers), leading to the suggestion that ε4 homozygosity may represent a distinct genetic type of AD. The aim of the present study was to investigate the role of ε4 homozygosity or heterozygosity in the presence or absence of the AD biomarker profile in patients with cognitive disorders in the Greek population. A total of 274 patients were included in the study. They underwent APOE genotyping and cerebrospinal fluid (CSF) biomarker profiling. The presence of ε4 was associated with a lower age of symptom onset and decreased amyloid biomarkers (irrespective to AD or non-AD profiles), and predicted the presence of an AD profile by a positive predictive value approaching 100%. In conclusion, the ε4 allele has a significant effect on the risk and clinical parameters of cognitive impairment and AD in the Greek population, while the ε4/ε4 genotype may be highly indicative of the (co)existence of AD in cognitively impaired patients.
- Open Access
- 13 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4221
Risk of Diabetes Mellitus in the Myasthenia Gravis: A Systematic Review and Meta-Analysis
Background/Objectives: Myasthenia gravis (MG) comprises an autoimmune disorder marked by muscle weakness and fatigue. MG frequently coexists with other autoimmune conditions, such as diabetes mellitus, which may exacerbate the clinical burden of MG and adversely impact overall quality of life. Methods: This systematic review and meta-analysis aimed to assess the prevalence of diabetes in patients with MG. Following PRISMA guidelines, a comprehensive search was conducted in the MEDLINE PubMed, Scopus, and Google Scholar databases. Results: A total of 11 studies comprising 16,825 patients were included. The pooled prevalence of diabetes among MG patients was 15.6% (95% CI [8.4%, 24.7%]; I2 = 99%, p < 0.001). Compared to healthy controls, MG patients had a 1.24-fold increased risk of developing diabetes (95% CI [1.01–1.54], p < 0.001). Meta-regression showed no association between age and diabetes prevalence, although potential publication bias was noted (Egger’s test, p = 0.72). Conclusions: This meta-analysis reveals a higher prevalence of diabetes among MG patients, with an elevated risk compared to healthy individuals. These findings suggest that the association between MG and diabetes may be mediated by corticosteroid use, genetic factors, and reduced physical activity. The main limitations of this study are the lack of reported data regarding the type of diabetes and patients’ demographic and disease characteristics (MG classification severity and duration and type of treatment). Further studies are needed to investigate the underlying causal mechanisms and to elucidate the relationship between MG and diabetes subtypes.
- 13 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4221
Open AccessRisk of Diabetes Mellitus in the Myasthenia Gravis: A Systematic Review and Meta-Analysis
Background/Objectives: Myasthenia gravis (MG) comprises an autoimmune disorder marked by muscle weakness and fatigue. MG frequently coexists with other autoimmune conditions, such as diabetes mellitus, which may exacerbate the clinical burden of MG and adversely impact overall quality of life. Methods: This systematic review and meta-analysis aimed to assess the prevalence of diabetes in patients with MG. Following PRISMA guidelines, a comprehensive search was conducted in the MEDLINE PubMed, Scopus, and Google Scholar databases. Results: A total of 11 studies comprising 16,825 patients were included. The pooled prevalence of diabetes among MG patients was 15.6% (95% CI [8.4%, 24.7%]; I2 = 99%, p < 0.001). Compared to healthy controls, MG patients had a 1.24-fold increased risk of developing diabetes (95% CI [1.01–1.54], p < 0.001). Meta-regression showed no association between age and diabetes prevalence, although potential publication bias was noted (Egger’s test, p = 0.72). Conclusions: This meta-analysis reveals a higher prevalence of diabetes among MG patients, with an elevated risk compared to healthy individuals. These findings suggest that the association between MG and diabetes may be mediated by corticosteroid use, genetic factors, and reduced physical activity. The main limitations of this study are the lack of reported data regarding the type of diabetes and patients’ demographic and disease characteristics (MG classification severity and duration and type of treatment). Further studies are needed to investigate the underlying causal mechanisms and to elucidate the relationship between MG and diabetes subtypes.